Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma
NiveshIQ
NSE: AUROPHARMA · Pharma
Aurobindo Pharma Ltd.
₹1,679.80▲ ₹11.40 (+0.68%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AUROPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Aurobindo Pharma Ltd.
Aurobindo Pharma Limited is a diversified generic pharmaceutical manufacturer headquartered in Hyderabad, India, with a global footprint in the United States, Europe, and other international markets. The company’s revenue mix is driven by finished dosage forms—including oral solids, liquids, and injectables—as well as active pharmaceutical ingredients (APIs) for CNS, anti‑retroviral, cardiovascular, antibiotics, gastroenterology, anti‑diabetic, and anti‑allergic indications. In FY27 Q2, the company reported a revenue of ₹34,935 crore and a net income of ₹3,713 crore, reflecting steady growth in both domestic and export segments. Recent developments include the launch of a generic Advair formulation, the establishment of a new subsidiary Avogent Lifesciences with a ₹5 crore capital infusion
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹29,002 Cr +16.70% | ₹31,724 Cr +9.40% | ₹33,653 Cr +6.10% |
| EBITDA Margin | 20.09% | 20.65% | 21.80% |
| Net Profit | ₹3,169 Cr +64.40% | ₹3,484 Cr +9.90% | ₹3,567 Cr +2.40% |
| EPS | ₹54.15 | ₹60.02 | ₹60.34 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Aurobindo Pharma Unit-IV API Facility Concludes US FDA Inspection With Zero Observations
Aurobindo Pharma Unit-IV API Facility Concludes US FDA Inspection With Zero Observations
🔒
+ 3 more stories about Aurobindo Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹9, 150 Cr, PAT ₹1, 032 Cr, EPS ₹17.86, EBITDA margin 23.4%. Growth context: revenue QoQ +3.4%, PAT QoQ +12.1%. Street verdict: inline, revenue surprise +1.6%, PAT surprise +3.9%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new product launches and ma...
FY26 (last completed FY): revenue ₹33, 653 Cr, PAT ₹3, 567 Cr, EBITDA margin 21.8%, EPS ₹60.34. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AUROPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AUROPHARMA alongside your other holdings
Unlock full AUROPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Aurobindo Pharma Ltd.?
NiveshIQ detects active intelligence signals for Aurobindo Pharma Ltd. (AUROPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Aurobindo Pharma Ltd.?
Aurobindo Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹8,625,484.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.